Markets
Bristol Myers Squibb: A Value Contender in Pharma
Bristol Myers Squibb (BMY) shows compelling value with a low forward P/E and a 4.2% dividend yield, despite concerns over legacy drug...
Bristol Myers Squibb (BMY) shows compelling value with a low forward P/E and a 4.2% dividend yield, despite concerns over legacy drug...